News Releases

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial
May 10, 2022
Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIVO
February 22, 2022
Zenith Epigenetics Announces Appointment to Board of Directors and Provides Clinical Update
January 31, 2022

About

Science & Epigenetics

Programs

Newsroom

Contact

© 2022 zenithepigenetics | Legal | Privacy

Bookmark and Share